Community Research and Development Information Service - CORDIS


RuPPIIs — Result In Brief

Project ID: 326744
Funded under: FP7-PEOPLE
Country: United Kingdom

Ruthenium at the ready to replace platinum in drugs

Ruthenium-based drugs have anti-cancer properties and could prove to be more effective alternatives to platinum-based drugs with fewer side-effects to boot. EU researchers studied the action of ruthenium-based protein inhibitors at the molecular level.
Ruthenium at the ready to replace platinum in drugs
The RUPPIIS (Ruthenium based protein-protein interaction inhibitor’s) project has synthesised novel fluorescent ruthenium-based bipyridine complexes that can penetrate the cell. Looking at the vast area where biological interactions take place, they observed how these molecules inhibit protein reactions that lead to disease development and progression.

Researchers designed, synthesised and looked at the behaviour and action mechanisms of a group of highly functionalised ruthenium (II) tris bipyridine complexes. Moreover, they resynthesised the original group of complexes with several additional entities. The focus was on selective high-affinity binding to protein surfaces, in particular cytochrome c, as well as efficient uptake into a line of human embryonic kidney cells.

Several of the compounds were taken up into cells and localised to cell organelles. Moreover, some compounds exerted a cytotoxic effect, probably through cell death, apoptosis. Potential applications include use of highly functionalised ruthenium (II) tris bipyridine complexes as cell permeable inhibitors of protein-protein interactions. They could also be used as imaging probes for diagnosis in the future.

The RUPPIIS project has demonstrated that ruthenium-based protein complexes could serve as tools for the investigation of reactions at the molecular level. Furthermore, they could act as sensors for malfunctioning proteins as well as aid in the development of new targeted molecular therapeutics.

Related information


Ruthenium, protein, disease development, cytochrome c, diagnosis, therapeutics
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top